EGFR and cancer: The selection of the FDA-approved gefitinib and erlotinib TKIs was based on the reported efficacy of these drugs in chemotherapeutic treatments of cancer patients with EGFR-induced tumors (Maemondo et al., 2010; Ciuleanu et al., 2012).